PIK3CA, and PTEN Aberrations in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors: Experience with 1,656 Patients at MD Anderson Cancer Center

Despite a wealth of preclinical studies, it is unclear whether PIK3CA or PTEN gene aberrations are actionable in the clinical setting. Of 1,656 patients with advanced, refractory cancers tested for PIK3CA or PTEN abnormalities, PIK3CA mutations were found in 9% (146/1,589), and PTEN loss and/or muta...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cell Rep
Autori principali: Janku, Filip, Hong, David S., Fu, Siqing, Piha-Paul, Sarina A., Naing, Aung, Falchook, Gerald S., Tsimberidou, Apostolia M., Stepanek, Vanda M., Moulder, Stacy L., Lee, J. Jack, Luthra, Rajyalakshmi, Zinner, Ralph G., Broaddus, Russell R., Wheler, Jennifer J., Kurzrock, Razelle
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4409143/
https://ncbi.nlm.nih.gov/pubmed/24440717
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2013.12.035
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi